Skip directly to page options Skip directly to A-Z link
Volume 23, Number 4—April 2017
Dispatch

Zika Virus Seroprevalence, French Polynesia, 2014–2015

Maite AubryComments to Author , Anita Teissier, Michael Huart, Sébastien Merceron, Jessica Vanhomwegen, Claudine Roche, Anne-Laure Vial, Sylvianne Teururai, Sébastien Sicard, Sylvie Paulous, Philippe Desprès, Jean-Claude Manuguerra, Henri-Pierre Mallet, Didier Musso, Xavier Deparis, and Van-Mai Cao-Lormeau
Author affiliations: Institut Louis Malardé, Papeete, Tahiti, French Polynesia (M. Aubry, A. Teissier, C. Roche, S. Teururai, D. Musso, V.-M. Cao-Lormeau); Centre d’Épidémiologie et de Santé Publique des Armées, Marseille, France (M. Huart, S. Sicard, X. Deparis); Unité Mixte de Recherche Sciences Economiques et Sociales de la Santé et Traitement de l'Information Médicale, Marseille (M. Huart, S. Sicard, X. Deparis); Institut de la Statistique de la Polynésie Française, Papeete (S. Merceron); Institut Pasteur, Paris, France (J. Vanhomwegen, S. Paulous, J.-C. Manuguerra); Direction Départementale de la Cohésion Sociale et de la Protection des Populations, Yonne, France (A.-L. Vial); Direction de la Santé de la Polynésie Française, Papeete (A.-L. Vial, H.-P. Mallet); Université de La Réunion and UMR PIMIT, Sainte Clotilde, France (P. Desprès)

Main Article

Table

Zika virus seroprevalence among persons randomly recruited from the general population and among schoolchildren immediately after and 18 months after a Zika outbreak, French Polynesia, 2014 and 2015*

Sampled population, time of sampling, location of sampling Median age (range), y No. symptomatic/no. positive (% [95% CI]) No. asymptomatic/no. positive (% [95% CI]) Total no. seropositive/total no. tested (% [95% CI])
General population
February–March 2014
Society Islands 47 (13–77) 8/18 (44 [26–69]) 10/18 (56 [33–79]) 18/49 (37 [26–47])
Tuamotu Islands 39 (7–86) 12/22 (55 [34–75]) 10/22 (45 [25–66]) 22/49 (45 [38–52])
Marquesas Islands 45 (10–82) 16/28 (57 [39–75]) 12/28 (43 [24–61]) 28/49 (57 [47–68])
Austral–Gambier Islands 38 (7–84) 19/29 (66 [48–83]) 10/29 (34 [17–52]) 29/49 (59 [39–80])
Total
 41 (7–86)
 55/97 (57 [47–67])
 42/97 (43 [33–53])
 97/196 (49 [42–57])
September–November 2015
Society Islands
 43 (4–88)
 73/154 (47 [40–55])
 81/154 (53 [45-61])
 154/700 (22 [16–28])
Schoolchildren
May–June 2014
Society Islands 11 (6–16) 221/312 (71 [66–76[) 91/312 (29 [24–34]) 312/476 (66 [60–71])

*CIs were calculated taking into account the cluster sampling design (9) and using the Fisher exact test.

Main Article

References
  1. Musso  D, Gubler  DJ. Zika Virus. Clin Microbiol Rev. 2016;29:487–524. DOIPubMedGoogle Scholar
  2. Cao-Lormeau  VM, Blake  A, Mons  S, Lastère  S, Roche  C, Vanhomwegen  J, et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387:1531–9. DOIPubMedGoogle Scholar
  3. Cauchemez  S, Besnard  M, Bompard  P, Dub  T, Guillemette-Artur  P, Eyrolle-Guignot  D, et al. Association between Zika virus and microcephaly in French Polynesia, 2013-15: a retrospective study. Lancet. 2016;387:2125–32. DOIPubMedGoogle Scholar
  4. Duffy  MR, Chen  TH, Hancock  WT, Powers  AM, Kool  JL, Lanciotti  RS, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009;360:2536–43. DOIPubMedGoogle Scholar
  5. Cao-Lormeau  VM, Roche  C, Teissier  A, Robin  E, Berry  A-L, Mallet  H-P, et al. Zika virus, French polynesia, South pacific, 2013. Emerg Infect Dis. 2014;20:1085–6. DOIPubMedGoogle Scholar
  6. Musso  D, Nilles  EJ, Cao-Lormeau  VM. Rapid spread of emerging Zika virus in the Pacific area. Clin Microbiol Infect. 2014;20:O595–6. DOIPubMedGoogle Scholar
  7. Mallet  HP, Vial  AL, Musso  D. Bilan de l’épidémie à virus Zika survenue en Polynésie française entre octobre 2013 et mars 2014. De la description de l’épidémie aux connaissances acquises après l’évènement. Bulletin épidémiologique hebdomadaire. 2016;20–21:367–73.
  8. Aubry  M, Finke  J, Teissier  A, Roche  C, Broult  J, Paulous  S, et al. Seroprevalence of arboviruses among blood donors in French Polynesia, 2011-2013. Int J Infect Dis. 2015;41:11–2. DOIPubMedGoogle Scholar
  9. Spiegel  A, Moulia-Pelat  J, Daumerie  D, Merlin  M, Baudon  D. Le sondage en grappe type OMS : méthodes pratiques en épidémiologie descriptive. Med Afr Noire. 1989;36:740–5.
  10. Musso  D, Nhan  T, Robin  E, Roche  C, Bierlaire  D, Zisou  K, et al. Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014. Euro Surveill. 2014;19:2pii=0761.
  11. Chungue  E, Marché  G, Plichart  R, Boutin  JP, Roux  J. Comparison of immunoglobulin G enzyme-linked immunosorbent assay (IgG-ELISA) and haemagglutination inhibition (HI) test for the detection of dengue antibodies. Prevalence of dengue IgG-ELISA antibodies in Tahiti. Trans R Soc Trop Med Hyg. 1989;83:708–11. DOIPubMedGoogle Scholar
  12. Dejnirattisai  W, Supasa  P, Wongwiwat  W, Rouvinski  A, Barba-Spaeth  G, Duangchinda  T, et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol. 2016;17:1102–8. DOIPubMedGoogle Scholar
  13. Priyamvada  L, Quicke  KM, Hudson  WH, Onlamoon  N, Sewatanon  J, Edupuganti  S, et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci U S A. 2016;113:7852–7. DOIPubMedGoogle Scholar
  14. Kucharski  AJ, Funk  S, Eggo  RM, Mallet  H-P, Edmunds  WJ, Nilles  EJ. Transmission dynamics of Zika virus in island populations: a modelling analysis of the 2013–14 French Polynesia outbreak. PLoS Negl Trop Dis. 2016;10:e0004726. DOIPubMedGoogle Scholar
  15. Johansson  MA, Hombach  J, Cummings  DA. Models of the impact of dengue vaccines: a review of current research and potential approaches. Vaccine. 2011;29:5860–8. DOIPubMedGoogle Scholar

Main Article

Page created: March 16, 2017
Page updated: March 16, 2017
Page reviewed: March 16, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external